Management of Pulmonary Embolism: State of the Art Treatment and Emerging Research
Vascular Disease (H Gornik and E Kim, Section Editors)
First Online: 02 February 2013 DOI:
Cite this article as: Esponda, O. & Tafur, A. Curr Treat Options Cardio Med (2013) 15: 137. doi:10.1007/s11936-013-0229-6 Opinion statement
Pulmonary embolism is one of the most important causes of morbidity and mortality in cardiovascular medicine and demands a circumscribed algorithmic treatment approach (Fig.
). Anticoagulation should be triggered by a high clinical probability and continued based on urgent definitive imaging. Our assessment then continues with evaluation of the clinical severity of the pulmonary embolism to determine whether the patient will benefit from thrombolysis or not. We usually reserve this option for cases of massive pulmonary embolism (sustained hypotension, pulselessness, or persistent profound bradycardia) or patients with a low cardiopulmonary reserve and categorical signs of right ventricle failure. At this juncture, renal function, a diagnosis of active cancer, calculated bleeding risk, and estimated patient compliance will help us gravitate toward specific agent selection for subsequent anticoagulation management. While rivaroxaban is an attractive oral therapy option, it is not an appropriate choice for patients with significant renal disease; patients with cancer are better treated with low molecular weight heparin when possible. Warfarin anticoagulation continues to be a well-known, valid, and cost-effective treatment option. At the end of the primary treatment we assess each patient for the likelihood of thromboembolism recurrence, which will be highest among those patients with idiopathic events or those with cancer-associated thrombosis. We favor prolonged anticoagulation in these scenarios. In addition, we strongly advocate periodic scheduled follow up of patients on long-term anticoagulation for secondary prophylaxis to re-evaluate their bleeding and recurrence risk. We understand both of these extremes are in a dynamic balance, and likewise so should be the anticoagulation directives. As we learn more about recurrence and bleeding prediction, we foresee a personalized approach in which the anticoagulant agent for each patient will be narrowly chosen based on their specific performance. 1 Keywords Pulmonary Embolism Anticoagulation Thrombolysis Treatment Venous Thromboembolism References and Recommended Reading Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Giuntini C, Di Ricco G, Marini C, et al. Pulmonary embolism: epidemiology. Chest. 1995;107:3S–9S.
Stein PD, Matta F. Epidemiology and incidence: the scope of the problem and risk factors for development of venous thromboembolism. Clin Chest Med. 2010;31:611–28.
Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation. 2012;125:e2–e220.
Masotti L, Ray P, Righini M, et al. Pulmonary embolism in the elderly: a review on clinical, instrumental and laboratory presentation. Vasc Health Risk Manag. 2008;4:629–36.
Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost. 2000;83:416–20.
Kline JA, Courtney DM, Kabrhel C, et al. Prospective multicenter evaluation of the pulmonary embolism rule-out criteria. J Thromb Haemost. 2008;6:772–80.
Le Gal G, Righini M, Roy PM, et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med. 2006;144:165–71.
Tapson VF. Advances in the diagnosis and treatment of acute pulmonary embolism. F1000 Med Rep. 2012;4:9.
Miniati M, Cenci C, Monti S, Poli D. Clinical presentation of acute pulmonary embolism: survey of 800 cases. PLoS One. 2012;7:e30891.
Schouten HJ, Koek HLD, Oudega R, et al. Validation of two age dependent D-dimer cut-off values for exclusion of deep vein thrombosis in suspected elderly patients in primary care: retrospective, cross sectional, diagnostic analysis. BMJ. 2012;344:e2985.
Stein PD, Hull RD, Patel KC, et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med. 2004;140:589–602.
Merli GJ. Low-molecular-weight heparin in the treatment of acute deep vein thrombosis and pulmonary embolism. Adv Stud Med. 2002;2:445–51. SRC - GoogleScholar.
Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e419S–94S. Updated most recent evidence based guidelines on venous thromboembolism.
Eichinger S, Kyrle PA. Medical therapy in venous thromboembolism. Semin Respir Crit Care Med. 2012;33:186–90.
Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366:1959–67.
Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367:1979–87.
Agterof MJ, Schutgens REG, Snijder RJ, et al. Out of hospital treatment of acute pulmonary embolism in patients with a low NT-proBNP level. J Thromb Haemost. 2010;8:1235–41.
Righini M, Roy PM, Meyer G, et al. The Simplified Pulmonary Embolism Severity Index (PESI): validation of a clinical prognostic model for pulmonary embolism. J Thromb Haemost. 2011;9:2115–7. Complements risk stratification strategies with goal of predicting morbidity and mortality at 30 days and allows for consideration of treatment of pulmonary embolism in the outpatient setting.
Zondag W, Mos ICM, Creemers-Schild D, et al. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost. 2011;9:1500–7.
Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123:1788–830. Defines key concepts in severity of pulmonary embolism and presents management algorithm according to clinical evaluation.
Bhoopat L, Rojnuckarin P, Hiransuthikul N, Intragumtornchai T. Low vegetable intake is strongly associated with venous thromboembolism in Thai population. Blood Coagul Fibrinolysis. 2010;21:758–63.
Hansen-Krone IJ, Enga KF, Njølstad I, et al. Heart healthy diet and risk of myocardial infarction and venous thromboembolism. The Tromsø Study. Thromb Haemost. 2012;108:554–60.
Lutsey PL, Steffen LM, Virnig BA, Folsom AR. Diet and incident venous thromboembolism: the Iowa Women's Health Study. Am Heart J. 2009;157:1081–7.
Varraso R, Kabrhel C, Goldhaber SZ, et al. Prospective study of diet and venous thromboembolism in US women and men. Am J Epidemiol. 2012;175:114–26.
Couris R, Tataronis G, McCloskey W, et al. Dietary vitamin K variability affects International Normalized Ratio (INR) coagulation indices. Int J Vitam Nutr Res. 2006;76:65–74.
Couris RR, Tataronis GR, Booth SL, et al. Development of a self-assessment instrument to determine daily intake and variability of dietary vitamin K. J Am Coll Nutr. 2000;19:801–7.
Holmes MV, Hunt BJ, Shearer MJ. The role of dietary vitamin K in the management of oral vitamin K antagonists. Blood Rev. 2012;26:1–14.
Borch KH, Hansen-Krone I, Braekkan SK, et al. Physical activity and risk of venous thromboembolism. The Tromso study. Haematologica. 2010;95:2088–94.
Hansen-Krone IJ, Enga KF. Lifestyle and venous thromboembolism : A review. 2011 (Master thesis). University of Tromsø, Tromsø, Norway. Retrieved from:
Enga KF, Brækkan SK, Hansen-Krone IJ, Hansen J-B. Emotional states and future risk of venous thromboembolism: the Tromsø Study. Thromb Haemost. 2012;107:485–93.
Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–53.
Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e24S–43S. Details pharmacological evidence based resourses for anticoagulation in the setting of pulmonary embolism.
Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. 2003;349 SRC - GoogleScholar:1695–1702.
Campbell NR, Hull RD, Brant R, et al. Aging and heparin-related bleeding. Arch Intern Med. 1996;156:857–60.
Warkentin TE, Pai M, Sheppard JI, et al. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost. 2011;9:2389–96.
Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012;120:4160–7.
Vavra KA, Lutz MF, Smythe MA. Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants. Ann Pharmacother. 2010;44:718–26.
LEXICOMP. Available at
. Accessed 18 Nov 2012.
Greinacher A, Völpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999;99:73–80.
Runyan CL, Cabral KP, Riker RR, et al. Correlation of bivalirudin dose with creatinine clearance during treatment of heparin-induced thrombocytopenia. Pharmacotherapy. 2011;31:850–6.
Eichler P, Lubenow N, Strobel U, Greinacher A. Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin. Blood. 2004;103:613–6.
Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol. 2011;72:581–92.
Bartholomew JR, Hursting MJ. Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR). J Thromb Thrombolysis. 2005;19:183–8.
Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e495S–530S.
Petros S. Lepirudin in the management of patients with heparin-induced thrombocytopenia. Biologics. 2008;2:481–90.
Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost. 2008;99:830–9.
Schulman S, Parpia S, Stewart C, et al. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med. 2011;155:653–9. W201.
Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. 2012;366 SRC - GoogleScholar:1287–1297.
ClinicalTrials.gov Available at
. Accessed 15 Jan 2013.
Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–52.
Guyatt GH, Akl EA, Crowther M, et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:7S–47S.
Coumadin [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2011.
Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol. 2012;26:27–32.
Dager WE, King JH, Regalia RC, et al. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy. 2006;26:1091–8.
Wozniak M, Kruit A, Padmore R, et al. Prothrombin complex concentrate for the urgent reversal of warfarin. Assessment of a standard dosing protocol. Transfus Apher Sci. 2012;46:309–14.
Yiu K-H, Siu C-W, Jim M-H, et al. Comparison of the efficacy and safety profiles of intravenous vitamin K and fresh frozen plasma as treatment of warfarin-related over-anticoagulation in patients with mechanical heart valves. Am J Cardiol. 2006;97:409–11.
Fugate JE, Rabinstein AA, McBane RD, Lanzino G. Dabigatran: A primer for Neurosurgeons. World neurosurgery 2012.
Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest. 2002;121:877–905.
Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation. 2004;110:744–9.
Stein PD, Matta F. Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. Am J Med. 2012;125:465–70.
Konstantinides SV, Meyer G, Lang I, Heart J. Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Am. 2012;163 SRC - GoogleScholar:33–38.
Goldhaber SZ, Kessler CM, Heit JA, et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol. 1992;20:24–30.
Meysman M, Haentjens P. Pulmonary embolism: current treatment options. Curr Treat Options Cardiovasc Med. 2005;7:483–90.
Becattini C, Agnelli G, Salvi A, et al. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res. 2010;125:e82–6.
Agnelli G, Becattini C, Kirschstein T. Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis. Arch Intern Med. 2002;162:2537–41.
Stein PD, Matta F, Steinberger DS, Keyes DC. Intracerebral hemorrhage with thrombolytic therapy for acute pulmonary embolism. Am J Med. 2012;125:50–6.
Sharifi M, Bay C, Skrocki L, et al. Moderate pulmonary embolism treated with thrombolysis: The MOPETT Trial. Presented at the American College of Cardiology (ACC) 2012 Scientific Sessions. Chicago, USA; March 24–27, 2012.
Berghaus TM, Thilo C, Bluethgen A, et al. Effectiveness of thrombolysis in patients with intermediate-risk pulmonary embolism: influence on length of hospital stay. Adv Ther. 2010;27:648–54.
DrugBank Available at
. Accessed 15 Jan 2013.
Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998;338:409–15.
Owens CA, Bui JT, Knuttinen MG, et al. Pulmonary embolism from upper extremity deep vein thrombosis and the role of superior vena cava filters: a review of the literature. J Vasc Interv Radiol. 2010;21:779–87.
Lynch FC. A method for following patients with retrievable inferior vena cava filters: results and lessons learned from the first 1,100 patients. J Vasc Interv Radiol. 2011;22:1507–12.
Uppal B, Flinn WR, Benjamin ME. The bedside insertion of inferior vena cava filters using ultrasound guidance. Perspect Vasc Surg Endovasc Ther. 2007;19:78–84.
Stawicki SP, Sims CA, Sharma R, et al. Vena cava filters: a synopsis of complications and related topics. J Vasc Access. 2008;9:102–10.
Imberti D, Ageno W, Manfredini R, et al. Interventional treatment of venous thromboembolism: a review. Thromb Res. 2012;129:418–25.
Verstraete M, Miller GA, Bounameaux H, et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation. 1988;77:353–60.
Stein PD, Alnas M, Beemath A, Patel NR. Outcome of pulmonary embolectomy. Am J Cardiol. 2007;99:421–3.
Sareyyupoglu B, Greason KL, Suri RM, et al. A more aggressive approach to emergency embolectomy for acute pulmonary embolism. Mayo Clin Proc. 2010;85:785–90.
Kadner A, Schmidli J, Schönhoff F, et al. Excellent outcome after surgical treatment of massive pulmonary embolism in critically ill patients. J Thorac Cardiovasc Surg. 2008;136:448–51.
Leacche M, Unic D, Goldhaber SZ, et al. Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg. 2005;129:1018–23.
Takahashi H, Okada K, Matsumori M, et al. Aggressive surgical treatment of acute pulmonary embolism with circulatory collapse. Ann Thorac Surg. 2012;94:785–91.
Kilic A, Shah AS, Merlo CA, et al. Early outcomes of antireflux surgery for United States lung transplant recipients. Surg Endosc 2012.
Meneveau N, Séronde M-F, Blonde M-C, et al. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest. 2006;129:1043–50.
Thielmann M, Pasa S, Wendt D, et al. Prognostic significance of cardiac troponin I on admission for surgical treatment of acute pulmonary embolism: a single-centre experience over more than 10 years. Eur J Cardiothorac Surg. 2012;42:951–7.
Rosenberger P, Shernan SK, Rawn JD, et al. Critical role of inferior vena caval filter placement after pulmonary embolectomy. J Card Surg. 2005;20:289–90.
Aymard T, Kadner A, Widmer A, J. Massive pulmonary embolism: surgical embolectomy versus thrombolytic therapy-should surgical indications be revisited? Eur Surg. 2012 SRC - GoogleScholar.
Malekan R, Saunders PC, Yu CJ, et al. Peripheral extracorporeal membrane oxygenation: comprehensive therapy for high-risk massive pulmonary embolism. Ann Thorac Surg. 2012;94:104–8.
PubMed CrossRef Copyright information
© Springer Science+Business Media New York 2013